Deferiprone is under clinical development by Chiesi Farmaceutici and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Deferiprone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Deferiprone (Ferriprox) is an iron chelating agent. It is formulated as solution, tablets and film coated tablets for oral route of administration. Ferriprox is indicated for the treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes and sickle cell disease or other anemias. Ferriprox is indicated for the treatment of patients with transfusional iron overload due to sickle cell disease or other anemias.
It is under development for the treatment of pantothenate kinase-associated neurodegeneration, Parkinson’s disease, amyotrophic lateral sclerosis and HIV. The drug candidate is administered orally and through intravenous route. The drug candidate was also under development for the treatment of Friedreich Ataxia.
Chiesi Farmaceutici overview
Chiesi Farmaceutici (Chiesi) researches, develops, produces and commercializes novel medicines with a focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome, lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD) and inflammatory bowel diseases, among others. The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and conducts research and development activities at its R&D center in Parma and at laboratories in Paris (France), Chippenham (the UK), Cary (the US) and Lidingo (Sweden). Chiesi is headquartered in Parma, Emilia-Romagna, Italy.
For a complete picture of Deferiprone’s drug-specific PTSR and LoA scores, buy the report here.